dapivirine ring previous safety experience mtn 020 training
TRANSCRIPT
![Page 1: Dapivirine Ring Previous Safety Experience MTN 020 Training](https://reader035.vdocuments.net/reader035/viewer/2022062720/56649f0d5503460f94c21980/html5/thumbnails/1.jpg)
Dapivirine RingPrevious Safety Experience
MTN 020 Training
![Page 2: Dapivirine Ring Previous Safety Experience MTN 020 Training](https://reader035.vdocuments.net/reader035/viewer/2022062720/56649f0d5503460f94c21980/html5/thumbnails/2.jpg)
What do we know?
Side effects Pregnancy Resistance
![Page 3: Dapivirine Ring Previous Safety Experience MTN 020 Training](https://reader035.vdocuments.net/reader035/viewer/2022062720/56649f0d5503460f94c21980/html5/thumbnails/3.jpg)
![Page 4: Dapivirine Ring Previous Safety Experience MTN 020 Training](https://reader035.vdocuments.net/reader035/viewer/2022062720/56649f0d5503460f94c21980/html5/thumbnails/4.jpg)
![Page 5: Dapivirine Ring Previous Safety Experience MTN 020 Training](https://reader035.vdocuments.net/reader035/viewer/2022062720/56649f0d5503460f94c21980/html5/thumbnails/5.jpg)
![Page 6: Dapivirine Ring Previous Safety Experience MTN 020 Training](https://reader035.vdocuments.net/reader035/viewer/2022062720/56649f0d5503460f94c21980/html5/thumbnails/6.jpg)
![Page 7: Dapivirine Ring Previous Safety Experience MTN 020 Training](https://reader035.vdocuments.net/reader035/viewer/2022062720/56649f0d5503460f94c21980/html5/thumbnails/7.jpg)
![Page 8: Dapivirine Ring Previous Safety Experience MTN 020 Training](https://reader035.vdocuments.net/reader035/viewer/2022062720/56649f0d5503460f94c21980/html5/thumbnails/8.jpg)
![Page 9: Dapivirine Ring Previous Safety Experience MTN 020 Training](https://reader035.vdocuments.net/reader035/viewer/2022062720/56649f0d5503460f94c21980/html5/thumbnails/9.jpg)
![Page 10: Dapivirine Ring Previous Safety Experience MTN 020 Training](https://reader035.vdocuments.net/reader035/viewer/2022062720/56649f0d5503460f94c21980/html5/thumbnails/10.jpg)
Same rate as no ring groups in previous studies
Metrorrhagia is common
![Page 11: Dapivirine Ring Previous Safety Experience MTN 020 Training](https://reader035.vdocuments.net/reader035/viewer/2022062720/56649f0d5503460f94c21980/html5/thumbnails/11.jpg)
![Page 12: Dapivirine Ring Previous Safety Experience MTN 020 Training](https://reader035.vdocuments.net/reader035/viewer/2022062720/56649f0d5503460f94c21980/html5/thumbnails/12.jpg)
![Page 13: Dapivirine Ring Previous Safety Experience MTN 020 Training](https://reader035.vdocuments.net/reader035/viewer/2022062720/56649f0d5503460f94c21980/html5/thumbnails/13.jpg)
![Page 14: Dapivirine Ring Previous Safety Experience MTN 020 Training](https://reader035.vdocuments.net/reader035/viewer/2022062720/56649f0d5503460f94c21980/html5/thumbnails/14.jpg)
![Page 15: Dapivirine Ring Previous Safety Experience MTN 020 Training](https://reader035.vdocuments.net/reader035/viewer/2022062720/56649f0d5503460f94c21980/html5/thumbnails/15.jpg)
Pregnancy In rats, some effects on the developing fetus were observed
following oral administration at maternally toxic doses (80 mg/kg and 320 mg/kg) of dapivirine
No effects in rats at the maternally non-toxic dose of 20 mg/kg/day, or in rabbits at up to 90 mg/kg.
Insufficient information is currently available on dapivirine administration in pregnant women
Measures should be taken to avoid dapivirine exposure in women of childbearing potential or during pregnancy
![Page 16: Dapivirine Ring Previous Safety Experience MTN 020 Training](https://reader035.vdocuments.net/reader035/viewer/2022062720/56649f0d5503460f94c21980/html5/thumbnails/16.jpg)
Resistance In vitro studies of dapivirine have shown that NNRTI
resistance mutants can develop when virus is cultured in the setting of low concentrations of dapivirine
Major mutations for resistance are Y181C, K103N, L100I and E138K
Clinical significance of these in vitro studies not known
![Page 17: Dapivirine Ring Previous Safety Experience MTN 020 Training](https://reader035.vdocuments.net/reader035/viewer/2022062720/56649f0d5503460f94c21980/html5/thumbnails/17.jpg)
Conclusions
Safety: To date, ring is safe and well tolerated No treatment-related SAEs Related AEs were similar in dapivirine and placebo
rings groups in IPM studies, and consistent with background rates in the general population.
![Page 18: Dapivirine Ring Previous Safety Experience MTN 020 Training](https://reader035.vdocuments.net/reader035/viewer/2022062720/56649f0d5503460f94c21980/html5/thumbnails/18.jpg)
Acknowledgements
IPM colleagues
![Page 19: Dapivirine Ring Previous Safety Experience MTN 020 Training](https://reader035.vdocuments.net/reader035/viewer/2022062720/56649f0d5503460f94c21980/html5/thumbnails/19.jpg)
Questions?